A Mixed Methods Evaluation of Pharmacists' Readiness to Provide Long-Acting Injectable HIV Pre-exposure Prophylaxis in California.

Autor:	Beltran RM; University of Minnesota, School of Public Health, Minneapolis, MN.; University of California, Los Angeles Luskin School of Public Affairs, Los Angeles, CA., Hunter LA; University of California, Berkeley School of Public Health, Berkeley, CA., Packel LJ; University of California, Berkeley School of Public Health, Berkeley, CA., De Martini L; California Society of Health-System Pharmacists, Sacramento, CA., Holloway IW; University of California, Los Angeles Luskin School of Public Affairs, Los Angeles, CA., Dong BJ; University of California, San Francisco School of Pharmacy, San Francisco, CA; and., Lam J; Chapman University, School of Pharmacy, Irvine, CA., McCoy SI; University of California, Berkeley School of Public Health, Berkeley, CA., Ochoa AM; University of California, Los Angeles Luskin School of Public Affairs, Los Angeles, CA.
Jazyk:	angličtina
Zdroj:	Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2024 Oct 01; Vol. 97 (2), pp. 142-149.
DOI:	10.1097/QAI.0000000000003470
Abstrakt:	Background: Pre-exposure prophylaxis (PrEP) uptake remains low among people who could benefit, some of whom may prefer alternatives to oral PrEP, such as long-acting injectable pre-exposure prophylaxis (LAI-PrEP). We evaluated the potential for LAI-PrEP provision in pharmacies through a mixed methods study of pharmacists in California, where Senate Bill 159 enables pharmacists to independently provide oral PrEP. Methods: In 2022-2023, we conducted an online cross-sectional survey of California pharmacists and pharmacy students (n = 919) and in-depth interviews with pharmacists (n = 30), both of which included modules assessing attitudes about PrEP provision. Using log-binomial regression, we estimated prevalence ratios (PRs) comparing survey participants' willingness to provide LAI-PrEP by pharmacy- and individual-level characteristics. Qualitative interview data were analyzed using Rapid Qualitative Analysis to identify factors that may affect pharmacists' provision of LAI-PrEP. Results: Half of the survey participants (53%) indicated that they would be willing to administer LAI-PrEP using gluteal injection in their pharmacy. Willingness was higher among participants who worked in pharmacies that provided vaccinations or other injections (56% vs. 46%; PR: 1.2; 95% confidence interval: 1.0-1.4) and/or oral PrEP under Senate Bill 159 (65% vs. 51%; PR: 1.3; 95% confidence interval: 1.1-1.5) than among participants whose pharmacies did not. Interviewed participants reported barriers to LAI-PrEP provision, including the need for increased training and staffing, a private room for gluteal injections, better medication access, and payment for services. Conclusion: Pharmacies offer a promising setting for increased LAI-PrEP access. However, pharmacists may require additional training, resources, and policy changes to make implementation feasible. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu